A randomized phase II study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy naive advanced pancreatic cancer preceded by a phase I portion.

Trial Profile

A randomized phase II study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy naive advanced pancreatic cancer preceded by a phase I portion.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2012

At a glance

  • Drugs Axitinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 31 Jul 2008 The expected completion date for this trial is now 1 Aug 2009 according to ClinicalTrials.gov.
    • 23 Sep 2007 Results presented at ECCO 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top